Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The present study investigated the prognostic role of extranodal extension (ENE) in stage III-N2 non-small-cell lung cancer (NSCLC) following curative surgery. From January 2005 to December 2018, pathologic stage III-N2 disease was diagnosed in 371 patients, all of whom underwent anatomic pulmonary resection accompanied by mediastinal lymph node dissection. This study included 282 patients, after excluding 89 patients who received preoperative chemotherapy or incomplete surgical resection. Their lymph nodes were processed; after hematoxylin and eosin staining, histopathologic slides of the metastatic nodes were reviewed by a designated pathologist. Predictors of disease free survival (DFS), including age, sex, operation type, pathologic T stage, nodal status, visceral pleural invasion, perioperative treatment, and the presence of ENE, were investigated. Among the 282 patients, ENE was detected in 85 patients (30.1%). ENE presence was associated with advanced T stage ( = 0.034), N2 subgroups ( < 0.001), lymphatic invasion ( = 0.001), and pneumonectomy ( = 0.002). The multivariable analysis demonstrated that old age ( < 0.001), advanced T stage ( = 0.012), N2 subgroups ( = 0.005), and ENE presence ( = 0.005) were significant independent predictors of DFS. The DFS rate at five years was 21.4% in patients who had ENE and 43.4% in patients who did not have ENE ( < 0.001). The presence of ENE, coupled with tumor-node-metastasis staging, should be recognized as a meaningful prognostic factor in stage III-N2 NSCLC patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347115PMC
http://dx.doi.org/10.3390/jcm10153324DOI Listing

Publication Analysis

Top Keywords

stage iii-n2
16
patients ene
12
extranodal extension
8
lymph nodes
8
iii-n2 non-small-cell
8
non-small-cell lung
8
lung cancer
8
ene
8
pathologic stage
8
patients
8

Similar Publications

Introduction: From the 1960s and up until 2021, neoadjuvant chemotherapy has represented the standard of care for potentially resectable stage III (N2) Non-Small Cell Lung Cancer (NSCLC). However, in recent years, immunotherapy in the form of Immune Checkpoint Inhibitors (ICIs) has revolutionized oncology treatment strategies and several ICIs have been investigated for the neoadjuvant treatment of NSCLC, both in monotherapy and in combination with other ICIs or chemotherapy.

Areas Covered: Therefore, this paper aims to review the currently available data supporting the role of immunotherapy in the neoadjuvant setting, as well as to discuss the challenges associated with it.

View Article and Find Full Text PDF

Treatment options for resectable stage III (N2) NSCLC have evolved rapidly over the last few years. However, an optimal treatment strategy has yet to be determined. In the below article, we present the results of LUN17-321 in the context of current treatment options available.

View Article and Find Full Text PDF

Introduction: Neoadjuvant or perioperative treatment, including an immune checkpoint inhibitor (ICI), has emerged as a new standard for patients with resectable stage III NSCLC. Nevertheless, approximately 20% of patients who start neoadjuvant chemo-immunotherapy will not undergo definitive surgery. Little is known about these patients.

View Article and Find Full Text PDF

: Lung cancer is the leading cause of cancer-related deaths worldwide and mediastinal lymph node involvement is an important negative prognostic factor. Nevertheless, the involvement of a single mediastinal nodal zone has been reported to have favorable outcomes. This study aims to assess whether the prognosis of non-small-cell lung cancer (NSCLC) with single-zone lymph node involvement varies by the affected lymph node zone.

View Article and Find Full Text PDF

Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L).

J Thorac Oncol

August 2025

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan; Izumi City General Hospital, Izumi, Japan; Department of Innovative Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Electronic address:

Introduction: Neoadjuvant chemo-immunotherapy is one of the standard treatment options for resectable stage II to III NSCLC. Nevertheless, this treatment yielded insufficient local control in the CheckMate 816 trial. We hypothesized that adding radiotherapy could improve local control, thereby improving survival outcomes.

View Article and Find Full Text PDF